Analogously, in the recent study by Vedamurthy et al. [26], they analyzed a cohort of IBD patients who reintroduced anti-TNFα or VDZ 1.3 to 3.9 years after cancer diagnosis and a subgroup of patients who did not interrupt therapy, and they did not find an increased risk of new or recurrent cancer in either the anti-TNFα or the VDZ group. This evidence concerns the gene TNF and inflammatory bowel disease.